Cargando…

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

BACKGROUND: Adalimumab is approved for the treatment of hidradenitis suppurativa (HS), plaque psoriasis, and other inflammatory conditions. OBJECTIVE: Our objective was to examine the safety of adalimumab administered every other week (EOW) and every week (EW) in patients with HS and psoriasis and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryan, Caitriona, Sobell, Jeffrey M., Leonardi, Craig L., Lynde, Charles W., Karunaratne, Mahinda, Valdecantos, Wendell C., Hendrickson, Barbara A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945711/ https://www.ncbi.nlm.nih.gov/pubmed/29380251 http://dx.doi.org/10.1007/s40257-017-0341-6

Ejemplares similares

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
por: Papp, Kim A., et al.
Publicado: (2015)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Which is the best schedule of autologous blood storage for pre-operative AIS patients? Every week or every 2 weeks
por: Tamai, Koji, et al.
Publicado: (2015)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
por: Gorovoy, Ian, et al.
Publicado: (2009)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials
por: van der Zee, H.H., et al.
Publicado: (2019)

Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice
por: Calvo Moya, Marta, et al.
Publicado: (2023)

As every year, 2016 ended with the Council Week
por: Staff Association
Publicado: (2017)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
por: Harvin, Glenn, et al.
Publicado: (2016)

Treatment of Hidradenitis Suppurativa Patient with Klinefelter Syndrome by Adalimumab
por: Shin, Ji Yeoun, et al.
Publicado: (2019)

Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa
por: Al-Tkrit, Amna, et al.
Publicado: (2021)

Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan
por: Hayashi, Nobukazu, et al.
Publicado: (2022)

Hidradenitis suppurativa and psoriasis: the odd couple
por: Macca, Laura, et al.
Publicado: (2023)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

‘I Know it was Every Week, but I Can't be Sure if it was Every Day: Domestic Violence and Women with Learning Disabilities
por: McCarthy, Michelle, et al.
Publicado: (2016)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
por: Fotiadou, Christina, et al.
Publicado: (2016)

Genital lymphedema associated with hidradenitis suppurativa unresponsive to adalimumab treatment
por: Musumeci, Maria Letizia, et al.
Publicado: (2019)

A complication in a patient with hidradenitis suppurativa taking adalimumab
por: Perez, Olivia D., et al.
Publicado: (2022)

Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa
por: Alnaif, Sarah, et al.
Publicado: (2023)

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
por: Taxonera, Carlos, et al.
Publicado: (2021)

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
por: Kimball, A.B., et al.
Publicado: (2015)

Health benefits of late-onset metformin treatment every other week in mice
por: Alfaras, Irene, et al.
Publicado: (2017)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
por: Kyriakou, Aikaterini, et al.
Publicado: (2018)

The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa
por: Frew, John W., et al.
Publicado: (2021)

Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment
por: IKEYA, Soichiro, et al.
Publicado: (2021)

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab
por: Saal, Ryan C., et al.
Publicado: (2023)

Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
por: Morita, Akimichi, et al.
Publicado: (2019)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa
por: Giesey, Rachel, et al.
Publicado: (2017)

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
por: Alam, Maryam Shayesteh, et al.
Publicado: (2020)

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
por: Blaszczak, Alecia, et al.
Publicado: (2020)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis
por: Tsentemeidou, Aikaterini, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2949bpaj70nkn8mh4bgtlgfa0t